Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.49 |
| ▸ | STAT3 | P40763 | 2/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868062 | 0.83 | MAOA (0.56) | MAOAALDH1A1MAPTTDP1MAPK1 | |
| SCHEMBL10037439 | 0.72 | MAOA (0.50) | MAOAALDH1A1MAPTTDP1MAPK1 | |
| SCHEMBL10037432 | 0.72 | MAOA (0.46) | MAOAALDH1A1MAPTTDP1MAPK1 | |
| SCHEMBL5809304 | 0.71 | HSP90AA1 (0.76) | MAOAALDH1A1MAPTMAPK1HPGD | |
| SCHEMBL868107 | 0.71 | MAOA (0.56) | MAOAALDH1A1MAPTTDP1MAPK1 | |
| SCHEMBL10067750 | 0.71 | MAOA (0.56) | MAOAALDH1A1MAPTTDP1MAPK1 | |
| Anthrarufin SCHEMBL187843 | 0.71 | MAOA (1.00) | MAOAALDH1A1MAPTTDP1MAPK1 | |
| Anthrarufin SCHEMBL29363946 | 0.71 | MAOA (1.00) | MAOAALDH1A1MAPTTDP1MAPK1 | |
| Anthrarufin SCHEMBL29874705 | 0.71 | MAOA (1.00) | MAOAALDH1A1MAPTTDP1MAPK1 | |
| SCHEMBL8153746 | 0.71 | MAOA (0.66) | MAOAALDH1A1HPGDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436669-B1 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | NR2C2, NR0B2, NR4A2 | MAOA 1290/4885ALDH1A1 862/4885MAPT 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.